GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Gross-Profit-to-Asset %

GlobeStar Therapeutics (GlobeStar Therapeutics) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. GlobeStar Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was $ 0 Mil. Therefore, GlobeStar Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was Not Available.


GlobeStar Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for GlobeStar Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Gross-Profit-to-Asset % Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -32.76 -4.17 - -

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, GlobeStar Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Gross-Profit-to-Asset % falls into.



GlobeStar Therapeutics Gross-Profit-to-Asset % Calculation

GlobeStar Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=0/( (0.01+0)/ 1 )
=0/0.01
=0.00 %

GlobeStar Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (0+0)/ 1 )
=0/0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


GlobeStar Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550